Table 1

Patient Demographics and Tumor Characteristics by Treatment Choice (N = 240)

VariableSurgery n = 137Radiation n = 72WW/AS n = 31P value
Age, mean (SD)59.4 (7.4)63.2 (7.2)64.3 (7.9)<.001
Age group, No. (%).002
 ≤65102 (74.5)41 (56.9)14 (45.2)
 >6535 (25.5)31 (43.1)17 (54.8)
Race, No. (%).81
 Black68 (49.6)36 (50.0)17 (54.8)
 White69 (50.4)36 (50.0)14 (45.2)
Education, No. (%).70
 ≤High school46 (34.1)25 (35.2)11 (35.5)
 Some college37 (27.4)27 (38.0)10 (32.3)
 College graduate27 (20.0)11 (15.5)5 (16.1)
 Some postgraduate study25 (18.5)8 (11.3)5 (16.1)
No. comorbidities, mean (SD)1.23 (1.0)1.75 (1.3)1.39 (1.0).01
General health perception, mean (SD)2.71 (0.84)2.41 (0.89)2.26 (0.89).008
Perceived cancer seriousness, mean (SD)3.8 (1.3)3.1 (1.3)2.9 (1.4)<.001
Worry about prostate cancer, mean (SD)2.5 (1.0)2.1 (0.9)2.4 (1.0).004
PSA level, No. (%).39
 ≤436 (26.9)22 (31.0)8 (28.6)
 5–980 (59.7)41 (57.7)15 (53.6)
 10–1915 (11.2)4 (5.6)5 (17.9)
 ≥203 (2.2)4 (5.6)0 (0.0)
Gleason score, No. (%).03
 ≤648 (35.3)30 (46.2)15 (50.0)
 779 (58.1)25 (38.5)11 (36.7)
 8–109 (6.6)10 (15.4)4 (13.3)
Stage, No. (%)<.001
 ≤T2a21 (15.4)51 (78.5)23 (76.7)
 T2b or T2NOS19 (14.0)8 (12.3)5 (16.7)
 ≥T2c96 (70.6)6 (9.2)2 (6.7)
Risk level, No. (%)<.001
 Low risk8 (5.9)26 (40.0)9 (30.0)
 Intermediate risk29 (21.3)23 (35.4)15 (50.0)
 High risk99 (72.8)16 (24.6)6 (20.0)
  • PSA = prostate-specific antigen; WW/AS = watchful waiting or active surveillance.

  • Note: The general health perceptions scale ranged from 1 (Poor) to 5 (Excellent), the perceived cancer seriousness scale ranged from 1 (Not at all Serious) to 5 (Very Serious), and the worry about prostate cancer scale ranged from 1 (Not at all) to 4 (Very Much).